Proven Executive Brings Both Clinical Trial Experience and Business
Development Leadership to Clinical Trial Services Management Role
CAMBRIDGE, Mass., Jan. 16 /PRNewswire/ -- Cytel, Inc. announced today that clinical research and business development executive Irving Dark has accepted the role of Vice President of Cytel Clinical Research Services. Mr. Dark brings to Cytel 15-years of management experience guiding drug, biologic and medical device products successfully through the development process as well as growing commercial clinical research organizations.
In his new position, Mr. Dark will head and drive the growth of Cytel's cutting-edge clinical trial design and implementation services to the biopharmaceutical industry.
Prior to joining Cytel, Mr. Dark was Vice President, Business Development and Operations for Veristat, Inc. During his tenure he established and oversaw the company's Data Management, Project Management, and Business Development departments. Mr. Dark was integrally involved with Veristat's Corporate Compliance activities to ensure adherence with regulatory and GCP guidelines, and was instrumental in the company's oncology and influenza contracts, and the Acambis smallpox vaccine program.
Previously, Mr. Dark held several key positions at full-service trial leader PAREXEL, rising from statistical programming management to overseeing the planning and conduct of phase 1, 2, and 3 global clinical trials.
"Irving's experience in trial management and his knowledge of the clinical development needs of the biopharmaceutical industry are ideally suited to growing Cytel's innovative clinical research services" said Ranganath Nayak, Chief Executive Officer of Cytel.
"Cytel has an impressive track record delivering innovative solutions
to the biopharmaceutical industry," said Irving Dark. "Cytel's experience
designing innovative clinical trials and its advanced analytical
|SOURCE Cytel Inc.|
Copyright©2008 PR Newswire.
All rights reserved